Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

Dank, M.; Zaluski, J.; Barone, C.; Valvere, V.; YALÇIN, SIDDIKA; Peschel, C.; Wenczl, M.; Goker, E.; Cisar, L.; Wang, K.; Bugat, R.

doi:10.1093/annonc/mdn166

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

Atıf İçin Kopyala

Dank M., Zaluski J., Barone C., Valvere V., YALÇIN S. S. , Peschel C., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.19, ss.1450-1457, 2008 (SCI İndekslerine Giren Dergi)

Cilt numarası: 19 Konu: 8
Basım Tarihi: 2008
Doi Numarası: 10.1093/annonc/mdn166
Dergi Adı: ANNALS OF ONCOLOGY
Sayfa Sayıları: ss.1450-1457

Özet

Background: We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive patients with adenocarcinoma of the stomach/esophagogastric junction.